
Nadine Petitpain

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7288439/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Fatal anaphylaxis with neuromuscular blocking agents: a risk factor and management analysis. Allergy: European Journal of Allergy and Clinical Immunology, 2014, 69, 954-959.	2.7	99
2	Anaesthetic hypersensitivity reactions in France between 2011 and 2012: the 10th <scp>GERAP</scp> epidemiologic survey. Acta Anaesthesiologica Scandinavica, 2017, 61, 290-299.	0.7	97
3	Hypersensitivity reactions during anesthesia. Results from the ninth French survey (2005-2007). Minerva Anestesiologica, 2012, 78, 868-78.	0.6	81
4	Neuromuscular blocking agents induced anaphylaxis: Results and trends of a French pharmacovigilance survey from 2000 to 2012. Allergy: European Journal of Allergy and Clinical Immunology, 2018, 73, 2224-2233.	2.7	32
5	Nicorandil and ulcerations: a NAD/NADP and nicotinic acid-dependent side-effect?. British Journal of Dermatology, 2008, 158, 1150-1151.	1.4	30
6	Role of nicotinic acid and nicotinamide in nicorandilâ€induced ulcerations: from hypothesis to demonstration. International Wound Journal, 2015, 12, 527-530.	1.3	17
7	Hepatitis B reactivation and immune check point inhibitors. Digestive and Liver Disease, 2021, 53, 452-455.	0.4	15
8	Tumor necrosis factor inhibitors added to nonbiological immunosuppressants vs. nonbiological immunosuppressants alone: a different signal of cancer risk according to the condition. A disproportionality analysis in a nationwide pharmacovigilance database. Fundamental and Clinical Pharmacology, 2016, 30, 162-171.	1.0	14
9	Nicorandil and ulcerations: the Trojan horse?. Journal of the European Academy of Dermatology and Venereology, 2012, 26, 925-926.	1.3	13
10	Nicorandil: from ulcer to fistula into adjacent organs. International Wound Journal, 2013, 10, 210-213.	1.3	12
11	A case of nicorandilâ€induced unilateral corneal ulceration. International Wound Journal, 2014, 11, 238-239.	1.3	12
12	Conjunctival and corneal ulcerations: keep a sharp eye on nicorandil. British Journal of Ophthalmology, 2012, 96, 463.2-464.	2.1	10
13	Detection of drug safety signals from clinical trials data: Role of SUSARs. Pharmacological Research, 2018, 131, 218-223.	3.1	10
14	Nicorandilâ€induced ulcerations: a 10â€year observational study of all cases spontaneously reported to the French pharmacovigilance network. International Wound Journal, 2018, 15, 508-518.	1.3	10
15	Drug adulteration of sexual enhancement supplements: a worldwide insidious public health threat. Fundamental and Clinical Pharmacology, 2021, 35, 792-807.	1.0	10
16	Serious adverse drug events related to non-investigational drugs in academic clinical trials: another source of safety data for risk assessment?. British Journal of Clinical Pharmacology, 2016, 82, 1069-1075.	1.1	5
17	ls <scp>TNF</scp> inhibitor exposure a risk factor for amyotrophic lateral sclerosis?. Fundamental and Clinical Pharmacology, 2019, 33, 689-694.	1.0	5
18	Recurrent Dysphonia and Acitretin. Journal of Voice, 2006, 20, 642-643.	0.6	4

NADINE PETITPAIN

#	Article	IF	CITATIONS
19	Overview of clinical trials vigilance units in French institutional sponsors – A study from the REVISE working group. Therapie, 2021, 76, 743-750.	0.6	1
20	Severe headaches and 3rd or 6th nerve palsy associated with nicorandil: A hypothesis. American Journal of Emergency Medicine, 2018, 36, 1500-1501.	0.7	0
21	La pholcodine est-elle un facteur de risque pour l'allergie aux myorelaxants�. Revue Francaise D'allergologie, 2018, 58, 155-156.	0.1	0